Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years | Synapse
April 18, 2026Open Access
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years
Key Points
This research aims to evaluate the long-term effectiveness and safety of avapritinib in treating chronic indolent systemic mastocytosis.
Conducted a long-term follow-up study
Included patients with chronic indolent systemic mastocytosis
Assessed the effectiveness and safety of avapritinib over three years
Avapritinib demonstrated effective long-term disease control
Well-tolerated with a favorable safety profile
Shows a positive benefit-risk balance for ongoing treatment
Abstract
Long-term follow-up (median, ∼3 years) demonstrates that avapritinib is effective and well tolerated. Avapritinib shows a favorable benefit-risk profile as a chronic ISM treatment.